CL2022003743A1 - Formulaciones de tableta dispersable que comprenden dolutegravir - Google Patents

Formulaciones de tableta dispersable que comprenden dolutegravir

Info

Publication number
CL2022003743A1
CL2022003743A1 CL2022003743A CL2022003743A CL2022003743A1 CL 2022003743 A1 CL2022003743 A1 CL 2022003743A1 CL 2022003743 A CL2022003743 A CL 2022003743A CL 2022003743 A CL2022003743 A CL 2022003743A CL 2022003743 A1 CL2022003743 A1 CL 2022003743A1
Authority
CL
Chile
Prior art keywords
dolutegravir
dispersible tablet
tablet formulations
formulations
treatment
Prior art date
Application number
CL2022003743A
Other languages
English (en)
Inventor
Paul Conn Ian
Robert Davies Mark
Heafield Joanne
Holton Michael
Mortimer Neil
Original Assignee
Viiv Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Co filed Critical Viiv Healthcare Co
Publication of CL2022003743A1 publication Critical patent/CL2022003743A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a formulaciones que comprenden dolutegravir o una sal farmacéuticamente aceptable del mismo, procesos para elaborar estas formulaciones y el uso de estas formulaciones en el tratamiento de la infección por VIH, en particular en el tratamiento de la infección por VIH en pacientes pediátricos.
CL2022003743A 2020-06-26 2022-12-23 Formulaciones de tableta dispersable que comprenden dolutegravir CL2022003743A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2009684.8A GB202009684D0 (en) 2020-06-26 2020-06-26 Formulations

Publications (1)

Publication Number Publication Date
CL2022003743A1 true CL2022003743A1 (es) 2023-06-30

Family

ID=71949817

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022003743A CL2022003743A1 (es) 2020-06-26 2022-12-23 Formulaciones de tableta dispersable que comprenden dolutegravir

Country Status (15)

Country Link
US (1) US20230285307A1 (es)
EP (1) EP4171572A1 (es)
JP (1) JP2023531086A (es)
KR (1) KR20230028288A (es)
CN (1) CN115697344A (es)
AR (1) AR122718A1 (es)
AU (1) AU2021296506A1 (es)
BR (1) BR112022026243A2 (es)
CA (1) CA3180544A1 (es)
CL (1) CL2022003743A1 (es)
GB (1) GB202009684D0 (es)
IL (1) IL298353A (es)
MX (1) MX2022015438A (es)
TW (1) TW202216154A (es)
WO (1) WO2021260567A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114191404B (zh) * 2022-01-10 2023-06-27 安徽贝克生物制药有限公司 一种多替拉韦片剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014125124A1 (en) * 2013-02-18 2014-08-21 Ratiopharm Gmbh Solid pharmaceutical dosage form of dolutegravir
WO2014184553A1 (en) * 2013-05-15 2014-11-20 Cipla Limited Pharmaceutical antiretroviral compositions
WO2015140569A1 (en) * 2014-03-20 2015-09-24 Cipla Limited Pharmaceutical composition
WO2016125192A2 (en) * 2015-02-06 2016-08-11 Mylan Laboratories Limited Process for the preparation of dolutegravir
US20180280401A1 (en) * 2015-10-14 2018-10-04 The Global Alliance For Tb Drug Development, Inc. Combination antibacterial composition and short-course antibacterial regimen

Also Published As

Publication number Publication date
AR122718A1 (es) 2022-09-28
JP2023531086A (ja) 2023-07-20
BR112022026243A2 (pt) 2023-01-17
KR20230028288A (ko) 2023-02-28
CA3180544A1 (en) 2021-12-30
EP4171572A1 (en) 2023-05-03
MX2022015438A (es) 2023-03-22
IL298353A (en) 2023-01-01
CN115697344A (zh) 2023-02-03
TW202216154A (zh) 2022-05-01
AU2021296506A1 (en) 2023-01-05
US20230285307A1 (en) 2023-09-14
GB202009684D0 (en) 2020-08-12
WO2021260567A1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
DOP2021000147A (es) Combinacion terapeutica que comprende lamivudina
MX2023006353A (es) Sistema ultravioleta para el tratamiento intracorporal.
CO2021007648A2 (es) 3,3- difluoroalilaminas o sales de las mismas y composiciones farmacéuticas que las comprenden
AR048324A1 (es) Metodos para tratar infecciones por vih
PE20171319A1 (es) Composiciones dispersables
MX2021006884A (es) Compuestos y su uso para el tratamiento de la deficiencia de alfa1-antitripsina.
CL2022003743A1 (es) Formulaciones de tableta dispersable que comprenden dolutegravir
CY1125075T1 (el) Εκχυλισμα salvia haenkei σαν δραστικος παραγοντας στις διαδικασιες επανεπιθηλιωσης και επουλωσης ιστων
WO2016086153A3 (en) Use of hsp90 inhibitors for the treatment of hiv infections and aids
BR112021018815A2 (pt) Gepotidacina para uso no tratamento de infecções bacterianas do trato urinário
CO2024006742A2 (es) Compuestos terapéuticos para la infección por el virus del vih
MX2020008360A (es) Forma cristalina de bictegravir sodico.
CO2023007851A2 (es) Proteínas de unión a il-7 y su uso en tratamientos médicos
ECSP22089498A (es) Inhibidores de il4i1 y métodos de uso
CL2022003712A1 (es) Formulaciones
CO2022002493A2 (es) Nanoemulsion de ácido 18p-glicirretínico
MX2019009810A (es) Formas cristalinas de cabotegravir de sodio.
CL2021003312A1 (es) Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.
MX2022001266A (es) Derivados de dihidropirimidina y usos de estos en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb.
WO2020139163A3 (ru) Комбинация противовирусных средств
GEP20227432B (en) Therapy of high-risk human papillomavirus infections
CL2018002378A1 (es) Medicamento útil como sustituto sanguineo para tratar, a la vez, la anemia aguda por pedida de sangre y la infección bacteriana en mamíferos
ECSP23031196A (es) Composición farmacéutica adecuada para administración vaginal en forma de óvulos y uso de la misma
AR108792A1 (es) Composiciones que comprenden timolol
TR201619953A2 (tr) Topi̇kal terapöti̇k formülasyonlar